Tango Therapeutics Posts Revenue Growth, Trials Underway

Tango Therapeutics reported a 52.15% week-on-week stock jump this week after Stifel reaffirmed a "buy" rating and as it begins clinical trials for vopimetostat in pancreatic cancer. The company said 2024 revenues rose 48.3% to $62.38 million and narrowed full-year net losses to $101.59 million, while fourth-quarter net loss widened to $38.7 million. It also partnered with Erasca for combination studies.